TABLE 3.

Network meta‐analysis for the remission of diabetes (follow‐up > 3 years)

BPD
16.85 (1.87, 152.08)	LAGB
7.93 (1.18, 53.28)	0.47 (0.08, 2.68)	LSG
5.10 (0.90, 28.75)	0.30 (0.06, 1.44)	0.64 (0.28, 1.46)	RYGBP
1.56 (0.13, 19.32)	0.09 (0.01, 1.01)	0.20 (0.04, 1.02)	0.31 (0.05, 1.92)	Mini‐GBP
54.12 (7.57, 387.05)	3.21(0.78, 13.15)	6.83 (1.47, 31.75)	10.62 (2.76, 40.89)	34.77 (3.65, 330.73)	NST

Note: Comparisons between drugs should be read from left to right. The estimates are located at the crossing between the column‐defining treatment and row‐defining treatment. An OR lower than 1 favours the column‐defining treatment. The significant results are presented in bold.

Abbreviations: BPD, biliopancreatic diversion without duodenal switch; CrI, credible interval; LAGB, laparoscopic‐adjustable gastric banding; LSG, laparoscopic sleeve gastrectomy; RYGBP, Roux‐en‐Y gastric bypass; mini‐GBP, single anastomosis (mini) gastric bypass; NST, non‐surgical treatment; OR, odds ratio.